ReviewFrontiers in immunology2026
Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiota in pancreatic cancer: Roles in tumor initiation and progression (Review).Oncology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advances in microbial sequencing technology, the role of microorganisms in cancer development and treatment has been increasingly explored. The gut microbiota, as a key shaper of both innate and adaptive immunity, is believed to migrate from the gut and colonize the pancreas, thereby influencing the tumor microenvironment(TME) of pancreatic cancer. Pancreatic cancer exhibits treatment resistance due to its immunosuppressive TME and high interstitial density. Multiple sequencing analyses of pancreatic tumor tissues have revealed that alterations in the tumor-associated microbiota are associated with prognosis and treatment response, suggesting that the microbiota may serve as a complementary modality in immunotherapy. This paper describes potential pathways by which the gut microbiota can migrate to the pancreas and analyzes changes in tumor microbiota composition. It also identifies microbiota types associated with prognosis, and summarizes treatment strategies leveraging the gut-pancreas axis to enhance the personalization and precision of care. It critically examines the limitations of existing research, and aims to leverage microbiome ecology to overcome the immune -suppressive barrier in pancreatic cancer and improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.